LIXT - Lixte Biotechnology Long-Term Liabilities to Capital

Lixte Biotechnology (LIXT) is operating in a mode of gradual liquidity burn to fund its trials. The share of long-term liabilities in equity demonstrates a balance between shareholders and creditors, with the latest parameter standing at 0.06. Business development relies on partnerships with institutes studying protein phosphatase inhibitors. The company's resilience is based on its scientific potential and patents, remaining independent of economic cycles.

The valuation of Lixte Biotechnology (LIXT) is driven by its success in developing oncology inhibitors, rendering the business independent of macroeconomic factors. By analyzing the share of long-term loans within the capital structure, we assess the ratio of liabilities with a maturity of over one year to equity. This metric measures the level of financial leverage and debt load risk. A decrease in this indicator minimizes the probability of default but limits the potential for returns. For the investor, this is a key indicator of the R&D cycle's sustainability.